ARTBIO Announces Appointment of Nicole Hadas as Chief Legal Officer

CAMBRIDGE, Mass.; OSLO, Norway – January 21, 2025 – ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), announces the appointment of Nicole (Nikki) Hadas as Chief Legal Officer. Nikki joins ARTBIO with more than 20 years of experience leading legal functions at life science companies in all stages of development, from pre-clinical through commercial. In this role, Nikki will oversee all aspects of corporate legal strategy, including managing regulatory compliance, corporate governance, risk management, business development, and intellectual property, to support the development and commercialization of ARTs.

"We are thrilled to have Nikki join our leadership team. Her vast experience in corporate law and strategic leadership, coupled with her ability to navigate complex legal landscapes, will be crucial as we continue to grow and advance our pipeline of ARTs,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO. “Nikki will be instrumental in shaping our legal and intellectual property strategy, strengthening our governance practices, and ensuring we meet regulatory requirements during this critical time in our company.”

Nikki joins ARTBIO from Akebia Therapeutics, where she served as Senior Vice President and Chief Legal Officer, helping lead the company as it grew from a private, clinical-stage organization to a public company with two commercial products. Prior to that, Nikki served as Senior Vice President and General Counsel at Inspiration Biopharmaceuticals, where she played a critical role in the successful sale of the company’s hemophilia assets. Nikki began her in-house legal career in life sciences at Genzyme Corporation where she supported various business units during her ten years with the company. Prior to Genzyme she was an associate at Foley Hoag, where she represented biopharmaceutical companies and healthcare providers in a wide range of legal matters. Nikki received a J.D. from Boston College Law School and a B.A. in Psychology from the University of Michigan.

"I am excited to join the team at ARTBIO as Chief Legal Officer,” said Nikki Hadas. “I look forward to leveraging my legal expertise to help enable ARTBIO’s mission of delivering innovative alpha radioligand therapies that make a meaningful difference for patients with cancer. I am eager to work with the ARTBIO team to navigate the unique regulatory, intellectual property, operational, and compliance challenges of the radiopharmaceutical industry, ensuring that we continue to drive growth, innovation, and strategic partnerships in this dynamic and rapidly evolving space.”

About ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (²¹²Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind ²¹²Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first-in-human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.